Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin 53705, USA.
Ann Thorac Surg. 2010 Jul;90(1):176-81. doi: 10.1016/j.athoracsur.2010.03.065.
The presentation, management, and outcome of patients with primary cardiac sarcomas are not well defined. Furthermore, the role of adjuvant therapy has not been delineated in the management of primary cardiac sarcomas.
Patients with primary cardiac sarcoma and noncardiac sarcoma, diagnosed between 1988 and 2005, were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Clinical characteristics and outcomes of primary cardiac sarcoma were defined and compared with the characteristics of noncardiac sarcomas. Univariate and multivariate methods were used to identify factors associated with primary cardiac sarcoma survival.
Compared with noncardiac sarcomas, primary cardiac sarcomas were found to occur in a younger age group and were more likely to present with advanced disease. Primary cardiac sarcomas were ten times more likely to be vessel-derived (eg, angiosarcoma), comprising almost half of all cases. Median overall survival for cardiac sarcoma patients was 6 months whereas that for noncardiac sarcoma patients was significantly longer at 93 months (p < 0.001). Furthermore, cardiac sarcoma patients who underwent surgery had a median survival of 12 months whereas those who did not undergo surgery had a median survival of 1 month (p < 0.001).
Cardiac sarcomas are a distinct, rare subset of soft tissue sarcomas with a poor prognosis. Surgery continues to be the central component of successful management. Future clinical efforts should be directed at developing approaches to permit safe radical excision and, potentially, developing effective adjuvant therapy.
原发性心脏肉瘤的临床表现、治疗及预后尚无明确定论。此外,辅助治疗在原发性心脏肉瘤的治疗中作用也尚未确定。
我们在监测、流行病学和最终结果(SEER)数据库中鉴定了 1988 年至 2005 年间诊断的原发性心脏肉瘤和非心脏肉瘤患者。定义了原发性心脏肉瘤的临床特征和结局,并与非心脏肉瘤的特征进行了比较。采用单变量和多变量方法确定与原发性心脏肉瘤生存相关的因素。
与非心脏肉瘤相比,原发性心脏肉瘤患者年龄更小,且更可能处于晚期疾病状态。原发性心脏肉瘤更可能来源于脉管系统(例如血管肉瘤),几乎占所有病例的一半。心脏肉瘤患者的中位总生存期为 6 个月,而非心脏肉瘤患者的中位总生存期显著更长,为 93 个月(p < 0.001)。此外,接受手术的心脏肉瘤患者的中位生存期为 12 个月,而未接受手术的患者的中位生存期仅为 1 个月(p < 0.001)。
心脏肉瘤是一种罕见的、独特的软组织肉瘤亚群,预后较差。手术仍然是成功治疗的核心部分。未来的临床研究应致力于开发安全根治性切除的方法,并有可能开发有效的辅助治疗方法。